Brain is a potential sanctuary for subtype C
HIV-1 irrespective of ART treatment outcome by Tso, For Yue et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Virology Papers Virology, Nebraska Center for 
2018 
Brain is a potential sanctuary for subtype C HIV-1 irrespective of 
ART treatment outcome 
For Yue Tso 
University of Nebraska-Lincoln, ftso2@unl.edu 
Guobin Kang 
University of Nebraska-Lincoln, gkang2@unl.edu 
Eun Hee Kwon 
University of Nebraska-Lincoln 
Peter Julius 
University Teaching Hospital 
Qingsheng Li 
University of Nebraska-Lincoln, qli4@unl.edu 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/virologypub 
 Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell and Developmental 
Biology Commons, Genetics and Genomics Commons, Infectious Disease Commons, Medical 
Immunology Commons, Medical Pathology Commons, and the Virology Commons 
Tso, For Yue; Kang, Guobin; Kwon, Eun Hee; Julius, Peter; Li, Qingsheng; West, John T.; and Wood, Charles, 
"Brain is a potential sanctuary for subtype C HIV-1 irrespective of ART treatment outcome" (2018). 
Virology Papers. 368. 
https://digitalcommons.unl.edu/virologypub/368 
This Article is brought to you for free and open access by the Virology, Nebraska Center for at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an 
authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
For Yue Tso, Guobin Kang, Eun Hee Kwon, Peter Julius, Qingsheng Li, John T. West, and Charles Wood 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
virologypub/368 
RESEARCH ARTICLE
Brain is a potential sanctuary for subtype C
HIV-1 irrespective of ART treatment outcome
For Yue Tso1, Guobin Kang1, Eun Hee Kwon1, Peter Julius2, Qingsheng Li1, John
T. West1, Charles Wood1*
1 Nebraska Center for Virology and the School of Biological Sciences, University of Nebraska-Lincoln,
Nebraska, United States of America, 2 Department of Pathology and Microbiology, University Teaching
Hospital, Nationalist Road, Lusaka, Zambia
* cwood1@unl.edu
Abstract
Subtype C HIV-1 is responsible for the largest proportion of people living with HIV-1 infec-
tion. However, there is limited information about the roles of the brain and its cell types as a
potential sanctuary for this subtype and how the sanctuary may be affected by the adminis-
tration of anti-retroviral therapy (ART). To address this issue, we collected postmortem
brain tissues from ART treated HIV-1 infected Zambian individuals who experienced com-
plete viral suppression and those who did not. Tissues from various brain compartments
were collected from each individual as frozen and formalin-fixed paraffin embedded brain
specimens, for detection and quantification of HIV-1 genomes and identification of the
infected cell type. Genomic DNA and RNA were extracted from frozen brain tissues. The
extracted DNA and RNA were then subjected to droplet digital PCR for HIV-1 quantification.
RNA/DNAscope in situ hybridization (ISH) for HIV-1 was performed on formalin-fixed paraf-
fin embedded brain tissues in conjugation with immunohistochemistry to identify the infected
cell types. Droplet digital PCR revealed that HIV-1 gag DNA and RNA were detectable in
half of the cases studied regardless of ART success or failure. The presence of HIV-1 lacked
specific tissue compartmentalization since detection was random among various brain tis-
sues. When combined with immunohistochemistry, RNA/DNAscope ISH demonstrated co-
localization of HIV-1 DNA with CD68 expressing cells indicative of microglia or peripheral
macrophage. Our study showed that brain is a potential sanctuary for subtype C HIV-1, as
HIV-1 can be detected in the brain of infected individuals irrespective of ART treatment out-
come and no compartmentalization of HIV-1 to specific brain compartments was evident.
Introduction
The introduction of combined anti-retroviral therapy (ART) has been an important milestone
in curtaining the HIV-1 AIDS epidemic and has led to drastic improvement in the prognosis
of HIV-1 infected individuals. Although the ART regimens have extended the life expectancy
of many individuals, prolonged treatment comes with an increased probability of adverse
effects [1]. Emergence of ART resistant HIV-1 variants and other non-AIDS associated
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complications such as HIV-1 associated neurocognitive disorders (HAND) and cancers con-
tinue to be problematic despite the effective use of ART [2]. Additionally, the high cost of ART
has placed a heavy financial burden on resource-limited countries, such as those in sub-Saha-
ran Africa, and such burden potentially limit the universal access and sustainability of ART
implementation in these countries [3].
The ability of HIV-1 to persist in the infected host under suppressive ART has proven to be
a formidable obstacle to the eradication of HIV-1. Despite its capacity to reduce productive
infectious HIV-1 in the peripheral circulation to undetectable levels, ART does not eradicate
latent HIV-1, and therefore treatment has to be lifelong without discontinuation. This may
prove financially difficult to sustain in perpetuity. Hence, there has been an emphasis on the
development of latency-reversing agents (LRAs) with the goal to reactivate latent HIV-1, fol-
lowed by therapeutic intervention in the “shock and kill” strategy [4]. However, for such
latency reversal strategies to be most effective, it requires a better understanding of where
latent HIV-1 sanctuaries exist in infected individuals, whether those sanctuaries are modulated
by treatment outcomes and vary with different HIV-1 subtypes.
The central nervous system (CNS) has been documented as a potential sanctuary for HIV-1
and the virus can readily be detected in the cerebrospinal fluid (CSF) early after HIV-1 infec-
tion [5, 6]. The CNS is protected by the blood-brain barrier (BBB) and is considered an immu-
nological and pharmacological privileged site to which ART has limited access [7–10]. Thus,
the CNS presents a favorable environment for HIV-1 persistence. The presence of HIV-1 in
the CNS has been associated with increased risk of developing HAND in HIV-1 infected indi-
viduals who are ART naïve or have experienced therapy failure [11]. Additionally, a substantial
proportion of ~18% HIV-1 infected individuals achieving viral suppression also experienced
neuropsychological impairment [12].
HIV-1 infection of the CNS has primarily been studied in subtype B HIV-1 infected indi-
viduals [5, 13, 14]. Despite the fact that subtype C HIV-1 is responsible for the largest propor-
tion of people living with HIV-1 infection, there is limited information about the roles of the
brain as a potential sanctuary for this subtype and how the sanctuary may be affected by the
administration of ART [15, 16]. The inaccessibility of brain tissues from HIV-1 infected indi-
viduals makes sampling difficult and any longitudinal study impossible. In this study, we were
able to collect postmortem brain tissues from ART treated, subtype C HIV-1 infected, individ-
uals from Zambia. We performed a cross-sectional examination for the presence of HIV-1 in
the brain tissues of those who were virally suppressed versus those who had experienced ART
failures. We utilized ultra-sensitive detection methods such as droplet digital-PCR (ddPCR)
and RNA/DNAscope in situ hybridization (ISH) in conjugation with traditional immunohis-
tochemistry (IHC) to detect low HIV-1 copy in the frozen and formalin-fixed paraffin embed-
ded brain tissues respectively [17–19]. Our study is significant as it addresses important
knowledge gaps as to whether the CNS can serve as a potential sanctuary for subtype C HIV-1
in infected individuals and how the sanctuary is impacted by ART treatment.
Materials and methods
Postmortem brain sample
Permission to conduct this study was obtained from the University of Zambia Biomedical
Research Ethics Committee and the Institutional Review Board of the University of Nebraska-
Lincoln. Upon notification of a death in the adult medical wards at the University Teaching
Hospital (UTH) in Zambia, family members of the deceased were approached by an experi-
enced team member. Grief counseling was offered to the family members present regardless of
their decision to consent or not. The goals of the study were then explained as well as the
Brain sanctuary for subtype C HIV-1
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procedures to be conducted for tissue collection during autopsy. For those that provided writ-
ten consent, postmortem samples were collected at 24 hours after death from the following
brain compartments: frontal lobe, cerebellum, hippocampus, basal ganglia, temporal lobe,
parietal lobe and occipital lobe. Representative tissue slice (at least 3 mm) for each brain com-
partment was dissected and divided for snap freezing in liquid nitrogen and fixation in 4%
paraformaldehyde for paraffin-embedding. Venous blood was also collected if possible.
RT-PCR for plasma HIV-1 RNA load
HIV-1 RNA was extracted from plasma with QIAamp Viral RNA Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol with on-column DNase I treatment. HIV-
1 plasma viral load was quantified with RNA UltraSense One-Step Quantitative RT-PCR Sys-
tem (Invitrogen, Waltham, MA) using the following conditions: 50˚C for 15 min; 95˚C for 2
min; 40 cycles at 95˚C for 15 sec and 60˚C for 1 min. The primers and probe target the HIV-1
gag as previously described [17]. AcroMetrix HIV-1 panel (ThermoFisher Scientific, Fremont,
CA) was used for standard curve.
Extraction of genomic DNA and RNA from postmortem brain tissues
250 to 300 mg of each fresh-frozen brain tissue were pulverized by cryo-cracking in liquid
nitrogen. Cryo-cracked tissues were incubated overnight at 55˚C with cell lysis solution and
proteinase K (Qiagen, Hilden, Germany). The sample was then chilled on ice for 5 mins before
the addition of protein precipitation solution, mix and spun twice at 2000 x g for 10 mins at
4˚C to pellet the protein precipitates. The supernatant was transferred to a new tube with gly-
cogen and isopropanol to precipitate both genomic DNA and RNA simultaneously. The mix-
ture was then spun at 2000 x g for 5 mins at 4˚C to pellet the genomic DNA and RNA. The
DNA/RNA pellet was washed twice with 70% ethanol, air-dried, resuspended in hydration
solution (Qiagen, Hilden, Germany) and incubated at 65˚C for 30 mins to dissolve the pellet.
To separate the genomic RNA from DNA, Ambion TRIzol LS reagent (Invitrogen, Wal-
tham, MA) was added to the genomic DNA/RNA solution according to the manufacturer’s
protocol. After phase separation, genomic RNA from the aqueous layer was extracted using
QIAgen miRNeasy mini kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol
with additional on-column DNase I treatment.
To extract the genomic DNA, the aqueous layer after phase separation was mixed with gly-
cogen and 100% ethanol for 5 mins before spun at 15000 x g for 5 mins at 4˚C. After the super-
natant was discarded, the genomic DNA pellet was washed twice with 0.1M sodium citrate in
10% ethanol for 30 mins at room temperature and spun at 15000 x g for 5 mins at 4˚C. The
genomic DNA pellet was then washed with 75% ethanol for 10 mins at room temperature,
spun at 15000 x g for 5 mins at 4˚C. The genomic DNA pellet was air-dried, resuspended in
hydration solution (Qiagen, Hilden, Germany) and incubated at 65˚C for 1 hr before over-
night incubation at room temperature to ensure the DNA pellet was completely solubilized.
The genomic DNA was then further purified through standard ethanol precipitation.
Concentration of the extracted genomic DNA and RNA was determined using Qubit dou-
ble-stranded DNA and RNA broad-range kits (Invitrogen, Waltham, MA), and measured by
Qubit fluorometer (Invitrogen, Waltham, MA).
ddPCR for HIV-1 DNA and RNA
HIV-1 copy numbers from the extracted genomic DNA and RNA were determined by ddPCR,
as previously described [17]. Briefly, for detection of HIV-1 DNA, the extracted genomic DNA
was first digested with restriction enzyme Msc I to reduce sample viscosity and increase
Brain sanctuary for subtype C HIV-1
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template accessibility. The target sequences does not contain Msc I recognition sites. Each DNA
ddPCR reaction consisted of 1X ddPCR supermix for probes (Biorad, Hercules, CA), 900 nM
each of HIV-1 gag forward and reverse primers, 250 nM FAM-labeled HIV-1 gag probe, tem-
plate DNA and top up to 20 μl with molecular grade water [17]. The reaction mixture was then
loaded into QX100 droplet generator (Biorad, Hercules, CA) for droplet emulsion generation
and PCR was performed with C1000 Touch Thermal Cycler (Biorad, Hercules, CA). Fluores-
cence signal was quantified and analyzed by the QX100 droplet reader (Biorad, Hercules, CA)
and QuantaSoft version 1.3.2.0 (Biorad, Hercules, CA) respectively. To determine the total
number of analyzed cells, a separate ddPCR reactions were performed against the beta-globin
gene. The cut-off value for ddPCR positivity was determined using the genomic DNA extracted
from a total of 6.74 x 107 cells from various brain tissues of an HIV-1 negative individual (44
years old, male, cause of death as cardiac arrest), and was consistently found to be at an average
of ~1 HIV-1 copy/106 cells. Brain tissue from a HIV-1 positive (30 years old, male, cause of
death as toxoplasmosis) ART naïve individual was used as positive control.
Detection of HIV-1 RNA was similar to the DNA method, except that the reaction mix con-
sisted of 1X One-Step RT-ddPCR supermix (Biorad, Hercules, CA) and an additional 1 mM of
manganese acetate solution. A total of 120 ng of genomic RNA from each brain compartment
was analyzed for HIV-1 gag RNA. The cut-off value for ddPCR positivity was determined
using genomic RNA extracted from the various brain tissues of an HIV-1 negative individual,
and signals above ~2 HIV-1 copies/μg of RNA input were determined to be true signals. The
mean viral copies and statistical analysis (Unpaired T test) were performed using GraphPad
Prism 5 (GraphPad Software, La Jolla, CA).
RNA/DNAscope ISH and IHC
HIV-1 DNA and RNA in brain tissues were detected using DNAscope ISH sense and antisense
riboprobes in combination with RNAscope 2.0 HD red reagent kit (Advanced Cell Diagnos-
tics, CA), respectively. The experiment was conducted according to kit’s instruction and previ-
ously reported protocol [20]. The ISH stained sections were then digitized using Aperio CS2
Scanscope (Leica Aperio, CA). For determining the cell types of HIV-1 RNA and DNA posi-
tive cells, the coverslip of viral RNA or viral DNA positive tissue sections were removed and
tissue sections were rehydrated and received antigen retrieval as previously reported [21].
CD68+ cells or CD4+ T cells were immunohistochemically stained with mouse anti-human
CD68 monoclonal antibody (KP1, 1:200, Abcam) or rabbit anti-human CD4 monoclonal anti-
body (EPR6855, 1:200, Abcam) and the signal was developed with the Dako Envision and Per-
oxidase kit using diaminobenzidine (DAB) as substrate. Stained sections were digitized and
CD68+ cells or CD4+ T cells were analyzed by Aperio’s Spectrum Plus analysis program (ver-
sion 9.1; Aperio ePathology Solutions) as described previously [22].
Results
A total of 8 HIV-1 positive individuals were studied. These subjects had been on ART for>6
months (range 9–108 months) prior to death (Table 1). The ART regimens of these subjects
were similar, consisting primarily of a protease inhibitor, nucleoside reverse transcriptase inhib-
itors and non- nucleoside reverse transcriptase inhibitors. Despite the administration of ART
over extended period of time, half of the cohort were considered to be ART failures given the
detectable plasma HIV-1 RNA ranging from 4 x 102 to 1 x 105 copies/ml (Table 1) despite treat-
ment for>6 months. The remainder were virally suppressed with undetectable plasma HIV-1
RNA by RT-PCR. There was no correlation between the duration of ART and the outcome of
Brain sanctuary for subtype C HIV-1
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ART therapy. The frontal lobe, cerebellum, hippocampus, basal ganglia, temporal lobe, parietal
lobe and occipital lobe of the brain from each subject were used for subsequent analyses.
Among the virally suppressed aviremic subjects, three out of four cases have detectable viral
DNA or RNA or both. One case (subject 245) has no statistical significant copies of either viral
DNA or RNA (Fig 1A and 1B). For subject 408, both viral DNA and RNA were detected in
some tissues. Low but statistical significance copies of HIV-1 gag DNA, at 3 copies/106 cells
(P = 0.0375) were detected in the basal ganglia (Fig 1A). The frontal lobe from this subject also
contained HIV-1 gag RNA at 27 copies/μg of genomic RNA input (P = 0.0013) (Fig 1B). For
subject 332 statistically significant HIV-1 gag RNA level was distinctly detected in the basal
ganglia and occipital lobe at 26 copies/μg of genomic RNA input (P = 0.0014) and 25 copies/μg
of genomic RNA input (P = 0.002), respectively (Fig 1B). However, even though some viral
DNA was only detected in occipital lobe but the copy number is too low to be significant.
Interestingly, for subject 328, low but consistent and statistically significant copies of viral
DNA were detected by ddPCR in the occipital lobe at 5 copies/106 cells (P < 0.0001). No sig-
nificant copy number of viral RNA was detected in any tissue tested for this subject.
Surprisingly, among the individuals failing to control viral load while on ART, only one of
four cases has detectable viral DNA and RNA. HIV-1 gag DNA that was statistically distinct
from the background was only detected in the basal ganglia of subject 319 that had the highest
level of HIV-1 gag DNA in the entire cohort, at 56 copies/106 cells (P< 0.0001) (Fig 2A). This
subject also had significant amount of HIV-1 gag RNA in the basal ganglia, temporal lobe and
occipital lobe at 52, 27 and 50 copies/μg of input genomic RNA respectively (Fig 2B). No signifi-
cant gag RNA was detected among the three ART failure individuals in their tested brain tissues.
The lack of detection for both the HIV-1 gag DNA and RNA in some of the brain samples
was not likely due to insufficient number of cells analyzed. On average, about 5 x 106 cellular
equivalents were used for ddPCR analysis for both the virally suppressed and ART failure cases
(Fig 3A and 3B respectively). Furthermore, the basal ganglia from subject 408 had the least
number of cells analyzed with only 2.6 x 106 cells (Fig 3A), but the HIV-1 gag DNA was still
detectable. The ddPCR detection of HIV-1 DNA and RNA from the brain tissues was con-
firmed with RNA/DNAscope ISH on selected tissues. For example, the presence of HIV-1
RNA and DNA were evident in the basal ganglia of ART failure subject 319, where both viral
Table 1. Subject demographic information.
Subject Age Sex Last known CD4 count
(cells/μl)
Plasma HIV-1 RNA load
(copies/ml)
ART duration
(months)
ART regiment
Clinical diagnosis
245 40 Male Undetermined Undetectable 48 Tenofovir, Emtricitabine,
Efavirenz
Cor pulmonale with cardiogenic shock
328 37 Male Undetermined Undetectable 10 Tenofovir, Emtricitabine,
Efavirenz
Meningo-encephalitis
332 37 Female Undetermined Undetectable 24 Tenofovir, Emtricitabine,
Efavirenz
Retroviral disease, upper gastrointestinal
tract bleeding, gastric ulcer
408 17 Male 900 Undetectable 108 Tenofovir, Emtricitabine,
Nevirapine
Retroviral disease, chronic meningitis
257 40 Male Undetermined 3 x 104 9 Tenofovir, Emtricitabine,
Efavirenz
Retroviral disease, anaemia
283 34 Female 300 4 x 102 36 Tenofovir, Emtricitabine,
Nevirapine
Retroviral disease, tuberculosis
309 34 Female 318 2 x 104 96 Tenofovir, Emtricitabine,
Efavirenz
Retroviral disease, cerebrovascular
accident
319 44 Female 70 1 x 105 24 Lopinavir, Abacavir,
Lamivudine
Retroviral disease, anaemia
https://doi.org/10.1371/journal.pone.0201325.t001
Brain sanctuary for subtype C HIV-1
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RNA and DNA expressing cells were detected (Fig 4A and 4B, respectively). Likewise, RNA/
DNAscope ISH results from a viral suppressed subject 408, whose basal ganglia had ddPCR
detectable viral DNA, but not viral RNA, showed only viral DNA positive cells (Fig 4C).
We then proceeded to determine the identity of the viral DNA positive infected cells in the
basal ganglia of subject 408 by performing IHC for CD4+ T cells or CD68+ expressing cells that
are indicative of microglia or peripheral macrophage, in conjunction with DNAscope ISH
against HIV-1 DNA. Although we only detected very few CD4+ T cells in the brain tissues (data
not shown), cells expressing CD68+ were readily detected in the brain tissues and, more impor-
tantly, overlapped with HIV-1 DNA signal from DNAscope ISH (Fig 4C, 4D and 4E). This result
suggests that microglia or peripheral macrophage that infiltrated the brain are the major cell
types infected by subtype C HIV-1 in the brain, at least based on the cases that we have analyzed.
Discussion
The existence of a brain sanctuary in HIV-1 infected individuals on suppressive ART is still
controversial and has not been studied extensively due to difficulties in obtaining tissues for
such analysis. In addition, most studies on HIV-1 infection of the central nervous system to
date have focused on subtype B strains [23, 24]. A previous study reported subtype C HIV-1
compartmentalization in the central nervous system in HIV-1 infected children [25]. How-
ever, that study only examined the cerebrospinal fluid without access to parenchymal brain
Fig 1. Droplet digital PCR detection of HIV-1 DNA and RNA in brain tissues of viral suppressed individuals. (A) HIV-1 gag DNA copies per million cells in various
brain tissues (B) HIV-1 gag RNA copies per million cells in various brain tissues. Basal Ganglia was not available for subject 245. P-value indicate statistically significant
from background/negative control. Dash lines indicate cut-off value for ddPCR positivity based on the negative control. Negative control derived from brain tissue of a
HIV-1 negative individual. Positive control derived from brain tissue of a HIV-1 positive but ART naïve individual.
https://doi.org/10.1371/journal.pone.0201325.g001
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tissues. Although another study had explored the presence of subtype C HIV-1 in brain tissues
from autopsy, it only examined proviral DNA in ART naïve cases [26]. It had no ART treated
cases for comparison and did not address the question of viral reactivation. Our postmortem
study design directly addresses the question of whether the brain can serve as a sanctuary for
subtype C HIV-1 by examining parenchymal tissues from sub-Saharan African ART treated
individuals. Subtype C HIV-1 is the dominant strain in Zambia and the subtype C classifica-
tion for our sample was also confirmed by sequencing for the viral envelope from subject 328
[27]. Our findings are particularly relevant since subtype C HIV-1 is the most prevalent strain
present in>50% of individuals living with HIV-1 worldwide.
HIV-1 infection is known to cause chronic inflammation, which could lead to dysregula-
tion of the tight junction between the brain microvascular endothelial cells and permeabiliza-
tion of the blood-brain barrier, thereby potentially increase HIV-1 infiltration into the brain
[28–30]. Additionally, the failure of ART to suppress the HIV-1 viral load in the peripheral
blood would have been predicted to increase the chances for HIV-1 to infect the CNS. Several
groups have previously reported that subtype B HIV-1 can be detected from the brain tissues
in about 50–55% of HIV-1 infected and ART treated patients [23, 31]. Similar to these reports,
our data also showed a 50% HIV-1 detection rate, with 4 out of the 8 subtype C HIV-1 infected
and ART treated subjects having detectable HIV-1 DNA or RNA in brain tissues. Despite the
lack of HIV-1 in most cases, we cannot rule out the presence of virus in these ‘negative’ sam-
ples since we can only analyzed a small section of each brain tissue, or the virus could be pres-
ent at a frequency below our detection limit. Nevertheless the detection of viral DNA in the
Fig 2. Droplet digital PCR detection of HIV-1 DNA and RNA in brain tissues of ART failure individuals. (A) HIV-1 gag DNA copies per million cells in various brain
tissues (B) HIV-1 gag RNA copies per million cells in various brain tissues. P-value indicate statistically significant from background/negative control. Dash lines indicate
cut-off value for ddPCR positivity based on the negative control. Negative control derived from brain tissue of a HIV-1 negative individual. Positive control derived from
brain tissue of a HIV-1 positive but ART naïve individual.
https://doi.org/10.1371/journal.pone.0201325.g002
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absence of viral RNA is of important even though we cannot determine whether the provial
DNA detected represent defective or intact viral genome. Surprisingly, our data did not show
differential HIV-1 infection frequency in the brains of ART failure cases compared to those
with fully suppressed peripheral viral load. One possible explanation is that, in addition to our
analyses were from a limited section of the brain tissues, subtype C HIV-1 might be less neuro-
tropic than subtype B. This notion may be supported by previous reports suggesting that sub-
type C HIV-1 causes less pathological changes in the brain than subtype B in both human
patients and experimentally infected animals [32, 33].
Previous studies have also suggested that certain brain compartments, such as the basal gan-
glia, temporal lobe and hippocampus, have an increased tendency to harbor HIV-1 [34, 35].
Although HIV-1 DNA or RNA was detected in the basal ganglia and temporal lobe from sev-
eral individuals in our study, we did not observe any obvious pattern in the distribution of
detectable events among the various brain compartments. Since our data revealed no specific
brain compartment as being more susceptible to subtype C HIV-1 infection than others, we
conclude that infection of the various brain compartments likely results from random events.
The distribution of detectable HIV-1 RNA was also not compartment-specific and more-
over did not correlate with the outcome of ART. Since we employed a primer set that targeted
the HIV-1 gag gene, which is typically encoded by genome length unspliced transcripts, we
eliminated the possibility of detecting prematurely terminated short viral transcripts derived
solely from the long-terminal repeat [36]. Detection of HIV-1 gag RNA in brain tissue,
strongly suggests that there could be persistent low-level viral replication or reactivation in the
brain tissues despite administration of ART. A recent non-human primate study with simian
immunodeficiency virus followed by comparative phylogenetic analysis of the viral sequences
in the cerebrospinal fluid versus plasma also suggested that HIV-1 can indeed be reactivated in
Fig 3. Number of cells analyzed by droplet digital PCR for HIV-1 DNA and RNA in brain tissues. (A) Viral suppressed subjects (B) ART failure subjects.
https://doi.org/10.1371/journal.pone.0201325.g003
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the brain [37, 38]. In contrast, some of our samples had detectable HIV-1 gag RNA but no
viral DNA. The detected virus, presumably in the vasculature, might therefore have originated
from an unsampled region within the same tissue, from other brain compartments, or even
from another peripheral tissue reservoir. It is also possible that viral DNA was present but sim-
ply below our detection limit, or we have missed the sections that were positive.
The precise mechanism that HIV-1 utilizes to enter the brain has not been absolutely
defined, but is thought to involve both infected T-cells and cell-free virions infiltrating past the
blood-brain barrier. Once in the brain parenchyma, HIV-1 cannot infect neurons, but is known
to infect CD68+ microglia [39, 40]. To identify the infected cell type in our cohort, we per-
formed IHC in conjunction with DNAscope ISH for HIV-1 DNA on selected brain tissues. Our
data showed that the HIV-1 DNA detected in the brain resides within CD68 expressing micro-
glia cells or brain-infiltrating peripheral macrophages. However, there are several limitations to
our present study. First is the small number of cases studied mainly due to the difficulties in
obtaining these postmortem cases especially in the African setting, a future study with a much
Fig 4. RNA/DNAscope in situ hybridization for HIV-1 RNA and DNA detection. (A) HIV-1 RNA in basal ganglia of subject 319. (B)
HIV-1 DNA in basal ganglia of subject 319. (C) HIV-1 DNA in basal ganglia of subject 408. (D) CD68 expression in basal ganglia of
subject 408 (E) Merged of HIV-1 DNA and CD68 expression in basal ganglia of subject 408. HIV-1 RNA/DNA positive signals are
shown as red color. Nucleus are shown as blue color. CD68 expression are shown as brown color. Green circles highlight representative
cells positive for HIV-1 RNA or DNA and/or CD68 expression.
https://doi.org/10.1371/journal.pone.0201325.g004
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larger cohort will be needed to support our preliminary findings. Furthermore, at this juncture,
it is not possible to determine whether the viral genomes detected are from intact and therefore
reactivable viral genomes or not since viral outgrowth assays have not yet been successfully per-
formed with postmortem brain tissues. Nevertheless, the presence of HIV-1 DNA in the
absence of viral RNA at least in one of our cases suggests the possibility of functional latent
sanctuary in the brain that could repopulate the periphery upon treatment cessation.
In conclusion, our study has shown that brain from subtype C HIV-1 infected individuals
can harbor viral genomes and can be a potential sanctuary, regardless of the peripheral success
or failure of ART. The virus appears to be randomly distributed among the various brain com-
partments with evidence of low copies of viral RNA in some cases, indicative of ongoing per-
sistent viral replication. Such a sanctuary may present a major challenge for HIV-1 treatments
as the capacity to penetrate the blood-brain barrier will need to be taken into consideration.
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